Please assess the completion status of the following clinical trial:

Trial Title: NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed consent form~* Age 18 or above at the time of selection~* In Vitro Fertilization referral~* Complete and normal pre-In Vitro Fertilization check-up~* Long protocol prescription~* No previous participation in the project during a previous cycle~Exclusion Criteria:~* Simultaneous participation in another interventional research project~* Contraindications of being pregnant or carrying a pregnancy to full term~* Contraindications of taking standard medication for long protocol~* Contraindications of taking Marvelon or using NuvaRing (Uncontrolled high blood pressure, uncontrolled diabetes, active hepatic infection, benign or malignant hepatic tumors, diagnosed breast cancer, diagnosed or suspected estrogen-dependant neoplasia, ocular or suspected lesion, history of thrombophlebitis, cardiac arrest, coronary heart disease.)~* Patient presenting vaginal abnormalities could be unable to insert the NuvaRing~* Cervicitis, vaginitis, erosio portionis bleeding, cervical prolapse, cystocele, rectocele, severe or chronic constipation, dyspareunia or other problems with sexual intercourse~* Patient having received research medication 30 days before visit 1~* Patient is unable to communicate adequately with researchers~* Patient is incapable of giving informed consent~* Any ovarian or abdominal abnormalities could interfere with an adequate sonographic evaluation~* Use of the following medication:~* Clonidine~* Anticoagulants (before the anovulant pre-treatment)~* Anticonvulsants~* Oral or insulin hypoglycemia drugs~* Hypertension drugs (beta blockers)~* Aminocaproic acid~* Beta mimetics (isoproterenol)~* Prednisone~* Ciclosporin~* Meperidine~* Phenothiazine and reserpine~* Chlordiazepoxide, Lorazepam, Oxazepam, Diazepam (during the anovulant pre-treatment)~* Theophylline~* Clomipramine~* Vitamin B12~* Hypericum perforatum-based products

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 43 Years
- Healthy Volunteers: f

Study Arms:
- NuvaRing (Type: EXPERIMENTAL): Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
- Marvelon (Type: ACTIVE_COMPARATOR): Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.

Based on this trial design, predict the completion outcome and termination type (if applicable).